Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Baxter Bros Inc.

Baxter Bros Inc. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,542 shares of the medical research company’s stock after purchasing an additional 5,985 shares during the period. Edwards Lifesciences comprises approximately 1.0% of Baxter Bros Inc.’s holdings, making the stock its 28th biggest holding. Baxter Bros Inc.’s holdings in Edwards Lifesciences were worth $6,904,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Nordea Investment Management AB lifted its stake in shares of Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after buying an additional 1,488,791 shares during the period. Telos Capital Management Inc. boosted its position in Edwards Lifesciences by 158.2% during the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC raised its position in Edwards Lifesciences by 5,092.4% in the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP boosted its position in shares of Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after buying an additional 2,043 shares during the period. Finally, HealthInvest Partners AB acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $1,587,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Evercore ISI cut their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $0.19 during trading hours on Friday, hitting $85.25. 2,327,197 shares of the stock were exchanged, compared to its average volume of 3,001,614. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company’s 50 day moving average is $90.08 and its 200 day moving average is $79.33. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm has a market capitalization of $51.37 billion, a P/E ratio of 36.75, a P/E/G ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. On average, research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the completion of the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total value of $2,487,999.50. Following the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $380,278.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 237,749 shares of company stock worth $20,920,934. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.